J Hypertens:短期血压变异性与肾病进展的相关性和预测作用

2018-07-12 xing.T MedSci原创

在CKD患者中,短期BPV与24h、夜间和白天血压密切相关,但不依赖于eGFR和蛋白尿,也不能预测CKD的进展。

在慢性肾病(CKD)患者中,很少有横断面研究证明动态血压(ABP)监测的短期血压变异性(BPV)与肾损伤之间存在关联。然而,没有研究评估短期BPV与CKD进展风险之间的关系。

近日,高血压领域权威杂志Journal of Hypertension上发表了一篇研究文章,研究人员进行了一项队列研究以评估G1-5期CKD的高血压患者短期BPV与肾脏结局事件的相关性和预测价值。作为短期BPV的指标,研究人员考虑了加权SD(W-SD)和SBP(CV-24-h SBP)的变异系数。该研究的主要结局为ESRD(慢性透析或移植)或GFR至少下降50%的复合终点。

研究人员纳入了465名患者(63.5±14.2岁; 54.7%为男性; eGFR:44±22ml/min/1.73 m2;蛋白尿:0.2[0.1-0.9]g/天); W-SD、CV-24-h SBP和24h SBP分别为12.5±3.3mmHg、11.1±2.8%和127±16mmHg。W-SD与年龄较大、心血管疾病史、糖尿病、高血压和多囊肾病的诊断以及24h SBP独立相关,而未发现与eGFR和蛋白尿相关。随访期间(中位数为6.4年),130例患者出现肾脏结局事件(107例ESRD,23例GFR下降≥50%)。较高的24h、白天和夜间SBP可强有力地预测复合肾脏终点[5 mmHg为1.18(1.10-1.25)],而由W-SD测量的BPV无论是作为连续变量[风险比为0.97(95%CI为0.91-1.04)]或按照三分位数作为分类变量[II和III三分位数分别有1.16(0.70-1.92)和0.95(0.54-1.68)]均不能预测复合肾脏终点。对于CV-24-h SBP也发现了类似的结果。

在CKD患者中,短期BPV与24h、夜间和白天血压密切相关,但不依赖于eGFR和蛋白尿,也不能预测CKD的进展。

原始出处:


Borrelli, Silvio.et al. Short-term blood pressure variability in nondialysis chronic kidney disease patients: correlates and prognostic role on the progression of renal disease. Journal of Hypertension. 2018.https://journals.lww.com/jhypertension/Abstract/publishahead/Short_term_blood_pressure_variability_in.97417.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2019-04-25 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2038945, encodeId=b750203894526, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Oct 05 08:19:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808917, encodeId=f44b180891efb, content=<a href='/topic/show?id=c5b68259068' target=_blank style='color:#2F92EE;'>#肾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82590, encryptionId=c5b68259068, topicName=肾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Aug 23 19:19:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837534, encodeId=4109183e534d8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Oct 14 21:19:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727433, encodeId=24a01e27433f1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Apr 25 21:19:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342498, encodeId=f903134249830, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 14 06:19:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031132, encodeId=d0b8103113204, content=#血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jul 12 18:19:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 心介

    #血压变异性#相信未来5年是热点,不仅关心血压高与低,还要关注血压变异性才可以

    0

相关资讯

Int J Cardiol:原籍对急性心肌梗死短期和长期预后的影响!

由此可见,移民会增加AMI出院后的风险,但AMI后住院死亡率不高。这些病人需要进行适当的有针对性的预防计划。

SCI REP:脓毒症患者短期和长期认知变化的相关因素!

一般来说,严重脓毒症或感染性休克患者存在的认知障碍可随着时间的推移而改善。这种改善与他们的ICU停留期间的因素有关,如认知储备、教育水平、在ICU停留期间的平均血糖以及NSE水平。

SCI REP:手术患者持续六小时以上手术的短期和长期结局如何?

在针对术后、术后一年内和术后五年内死亡率的多变量分析中,术后白蛋白浓度、ASA评分、ICU住院时间超过7天是患者依赖性的显著独立预测指标。手术时间延长会带来显著增加的短期、长期死亡率和致残率。

Diabetes Obes Metab:钠-葡萄糖协同转运体-2抑制剂的短期和中期疗效分析!

由此可见,SGLT-2抑制剂具有良好的持久性效果,至少长达两年,显著优于DPP-4I。磺脲类药物在短期内有效,但长期效果欠佳。